Analysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock Split

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) earns a place on our top 10 stocks under $5 that could triple.

As of March 19, 2026, 83% of covering analysts maintain bullish ratings for Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) with a consensus price target of $40.00, indicating 2,073.91% upside despite share price pressure.

Nevertheless, D. Boral Capital took a more cautious approach by downgrading Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)’s stock from “Buy” to “Hold” after the company announced a reverse stock split. These developments temper the confidence shown by investors, according to the firm. D. Boral Capital further added that although these moves do not change the underlying fundamentals, they have historically been followed by continued pressure on equities and are frequently linked to poor share price performance, often reflecting efforts to preserve compliance with exchange listing requirements.

This event follows the company’s filing of a 1-for-20 reverse stock split on March 4, 2026. Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) shares will continue to trade under the “RVPH” symbol on a split-adjusted basis, with no change in proportional shareholder control.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is a clinical-stage biopharmaceutical company focusing on the development of therapies for CNS, respiratory, and metabolic disorders. The company’s primary candidate, brilaroxazine, is designed to address neuropsychiatric indications through proprietary chemical genomics platforms.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.